Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

170105

registered interest
date	12/12/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, if he will make an assessment of the potential merits of allowing two Patient Access Schemes for one treatment; and if he will make a statement.
tabling member constituency	Southend West
tabling member printed	Mr David Amess
uin	218554
answer	answer is ministerial correction date of answer 17/12/2014 answer text <p>Whilst we recognise there are benefits to be derived from Patient Access Schemes (PAS), both the 2009 and 2014 Pharmaceutical Price Regulation Schemes (PPRS), negotiated with the United Kingdom pharmaceutical industry, set out that PAS should be the exception rather than the rule. It is important that PAS are operationally manageable for the National Health Service, and any burden for the NHS should be proportionate to the benefits of the PAS for the NHS and patients.</p><p> </p><p> </p><p> </p><p>The 2009 and 2014 schemes set out the Department’s and the Association of the British Pharmaceutical Industry’s commitment to ensure that the cumulative burden on all parties involved in the operation of PAS is manageable. The PPRS recognises that it is reasonable for the Department to take this issue into account when considering the viability of individual PAS proposals.</p><p> </p><p> </p><p> </p><p>The 2014 PPRS states that the Department is unlikely to agree more than one PAS for a single product because of the complexity this would introduce for the NHS.</p><p> </p><p><strong> </strong></p><p> </p><p> </p><p> </p><p> </p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 218458 question first answered 17/12/2014 17:16:52 answering member 4020 label Biography information for George Freeman
tabling member	44 label Biography information for Sir David Amess

169978

registered interest
date	11/12/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, whether his Department has any plans to allow two Patient Access Schemes for one treatment; and if he will make a statement.
tabling member constituency	Southend West
tabling member printed	Mr David Amess
uin	218458
answer	answer is ministerial correction date of answer 17/12/2014 answer text <p>Whilst we recognise there are benefits to be derived from Patient Access Schemes (PAS), both the 2009 and 2014 Pharmaceutical Price Regulation Schemes (PPRS), negotiated with the United Kingdom pharmaceutical industry, set out that PAS should be the exception rather than the rule. It is important that PAS are operationally manageable for the National Health Service, and any burden for the NHS should be proportionate to the benefits of the PAS for the NHS and patients.</p><p> </p><p> </p><p> </p><p>The 2009 and 2014 schemes set out the Department’s and the Association of the British Pharmaceutical Industry’s commitment to ensure that the cumulative burden on all parties involved in the operation of PAS is manageable. The PPRS recognises that it is reasonable for the Department to take this issue into account when considering the viability of individual PAS proposals.</p><p> </p><p> </p><p> </p><p>The 2014 PPRS states that the Department is unlikely to agree more than one PAS for a single product because of the complexity this would introduce for the NHS.</p><p> </p><p><strong> </strong></p><p> </p><p> </p><p> </p><p> </p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 218554 question first answered 17/12/2014 17:16:52 answering member 4020 label Biography information for George Freeman
tabling member	44 label Biography information for Sir David Amess

169883

registered interest
date	10/12/2014
answering body	Ministry of Justice
answering dept id	54
answering dept short name	Justice
answering dept sort name	Justice
hansard heading	Crime: Victims
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Justice, what steps the Government is taking to increase the compensation paid by criminals to their victims.
tabling member constituency	Southend West
tabling member printed	Mr David Amess
uin	906656
answer	answer is ministerial correction date of answer 16/12/2014 answer text <p>This Government takes enforcement of compensation orders very seriously and remains determined to find new ways to ensure they are paid and to trace those who do not pay. The Government has recently discussed with the Victims Panel how we might potentially pay compensation to victims up front, rather than victims having to wait for their money.</p> answering member constituency Hemel Hempstead answering member printed Mike Penning question first answered 16/12/2014 16:52:44 answering member 1528 label Biography information for Sir Mike Penning
tabling member	44 label Biography information for Sir David Amess

168962

registered interest
date	09/12/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pneumococcal Disease: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, with reference to the contribution by the Parliamentary Under-Secretary of State for Quality on 3 November 2014, House of Lords Official Report, column 1422, what the (a) membership and (b) terms of reference of the pneumococcal sub-committee of the Joint Committee on Vaccination and Immunisation will be.
tabling member constituency	Southend West
tabling member printed	Mr David Amess
uin	217920
answer	answer is ministerial correction date of answer 16/12/2014 answer text <p>The advice of Joint Committee on Vaccination and Immunisation (JCVI) Sub-committees is considered by the JCVI, often alongside key evidence on which the advice is based. Following consideration of the evidence, the JCVI will make a decision on adoption of the Sub-committee’s advice.</p><p> </p><p> </p><p> </p><p>The JCVI review of the adult pneumococcal vaccination programme will begin in spring 2015, with a review of the relevant evidence being undertaken by a JCVI Pneumococcal Sub-committee. As set out in the JCVI Code of Practice, the JCVI will consider the advice of the Sub-committee and may decide to issue an interim statement for a short period of consultation with those stakeholders who submitted evidence that informed the Committee’s advice.</p><p> </p><p> </p><p> </p><p>The role of JCVI Sub-committees and the mechanism for selection of Sub-committee membership is described in the JCVI Code of Practice. The membership of established sub-committees is set out in minutes of the meetings and on the GOV.UK web site at:</p><p> </p><p> </p><p> </p><p><a href="https://www.gov.uk/government/groups/joint-committee-on-vaccination-and-immunisation" target="_blank">https://www.gov.uk/government/groups/joint-committee-on-vaccination-and-immunisation</a>.</p><p> </p><p> </p><p> </p><p>Draft terms of reference for the JCVI Pneumococcal Sub-committee will be considered and agreed at the first meeting of the sub-committee and recorded in the minute of the meeting.</p><p> </p><p> </p><p> </p><p>The JCVI Code of Practice is available at:</p><p> </p><p><a href="https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/224864/JCVI_Code_of_Practice_revision_2013_-_final.pdf" target="_blank">https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/224864/JCVI_Code_of_Practice_revision_2013_-_final.pdf</a></p><p> </p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 217918 217919 question first answered 16/12/2014 17:17:39 answering member 3918 label Biography information for Jane Ellison
tabling member	44 label Biography information for Sir David Amess

168963

registered interest
date	09/12/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pneumococcal Disease: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, with reference to the contribution by the Parliamentary Under-Secretary of State for Quality on 3 November 2014, House of Lords Official Report, column 1422, what opportunities there will be for external stakeholders to contribute to the Joint Committee on Vaccination and Immunisation's review of adult pneumococcal vaccination.
tabling member constituency	Southend West
tabling member printed	Mr David Amess
uin	217919
answer	answer is ministerial correction date of answer 16/12/2014 answer text <p>The advice of Joint Committee on Vaccination and Immunisation (JCVI) Sub-committees is considered by the JCVI, often alongside key evidence on which the advice is based. Following consideration of the evidence, the JCVI will make a decision on adoption of the Sub-committee’s advice.</p><p> </p><p> </p><p> </p><p>The JCVI review of the adult pneumococcal vaccination programme will begin in spring 2015, with a review of the relevant evidence being undertaken by a JCVI Pneumococcal Sub-committee. As set out in the JCVI Code of Practice, the JCVI will consider the advice of the Sub-committee and may decide to issue an interim statement for a short period of consultation with those stakeholders who submitted evidence that informed the Committee’s advice.</p><p> </p><p> </p><p> </p><p>The role of JCVI Sub-committees and the mechanism for selection of Sub-committee membership is described in the JCVI Code of Practice. The membership of established sub-committees is set out in minutes of the meetings and on the GOV.UK web site at:</p><p> </p><p> </p><p> </p><p><a href="https://www.gov.uk/government/groups/joint-committee-on-vaccination-and-immunisation" target="_blank">https://www.gov.uk/government/groups/joint-committee-on-vaccination-and-immunisation</a>.</p><p> </p><p> </p><p> </p><p>Draft terms of reference for the JCVI Pneumococcal Sub-committee will be considered and agreed at the first meeting of the sub-committee and recorded in the minute of the meeting.</p><p> </p><p> </p><p> </p><p>The JCVI Code of Practice is available at:</p><p> </p><p><a href="https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/224864/JCVI_Code_of_Practice_revision_2013_-_final.pdf" target="_blank">https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/224864/JCVI_Code_of_Practice_revision_2013_-_final.pdf</a></p><p> </p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 217918 217920 question first answered 16/12/2014 17:17:38 answering member 3918 label Biography information for Jane Ellison
tabling member	44 label Biography information for Sir David Amess

168964

registered interest
date	09/12/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pneumococcal Disease: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, with reference to the contribution by the Parliamentary Under-Secretary of State for Quality on 3 November 2014, House of Lords Official Report, column 1422, whether the recommendations made by the pneumococcal disease sub-committee of the Joint Committee on Vaccination and Immunisation (JCVI) will be adopted by the JCVI upon completion of the sub-committee's work.
tabling member constituency	Southend West
tabling member printed	Mr David Amess
uin	217918
answer	answer is ministerial correction date of answer 16/12/2014 answer text <p>The advice of Joint Committee on Vaccination and Immunisation (JCVI) Sub-committees is considered by the JCVI, often alongside key evidence on which the advice is based. Following consideration of the evidence, the JCVI will make a decision on adoption of the Sub-committee’s advice.</p><p> </p><p> </p><p> </p><p>The JCVI review of the adult pneumococcal vaccination programme will begin in spring 2015, with a review of the relevant evidence being undertaken by a JCVI Pneumococcal Sub-committee. As set out in the JCVI Code of Practice, the JCVI will consider the advice of the Sub-committee and may decide to issue an interim statement for a short period of consultation with those stakeholders who submitted evidence that informed the Committee’s advice.</p><p> </p><p> </p><p> </p><p>The role of JCVI Sub-committees and the mechanism for selection of Sub-committee membership is described in the JCVI Code of Practice. The membership of established sub-committees is set out in minutes of the meetings and on the GOV.UK web site at:</p><p> </p><p> </p><p> </p><p><a href="https://www.gov.uk/government/groups/joint-committee-on-vaccination-and-immunisation" target="_blank">https://www.gov.uk/government/groups/joint-committee-on-vaccination-and-immunisation</a>.</p><p> </p><p> </p><p> </p><p>Draft terms of reference for the JCVI Pneumococcal Sub-committee will be considered and agreed at the first meeting of the sub-committee and recorded in the minute of the meeting.</p><p> </p><p> </p><p> </p><p>The JCVI Code of Practice is available at:</p><p> </p><p><a href="https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/224864/JCVI_Code_of_Practice_revision_2013_-_final.pdf" target="_blank">https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/224864/JCVI_Code_of_Practice_revision_2013_-_final.pdf</a></p><p> </p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 217919 217920 question first answered 16/12/2014 17:17:38 answering member 3918 label Biography information for Jane Ellison
tabling member	44 label Biography information for Sir David Amess

167508

registered interest
date	02/12/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Thalidomide
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, if he will request a meeting with the German Federal Minister for Family Affairs, Senior Citizens, Women and Youth to discuss possible compensation from the German government for British survivors of thalidomide; and if he will make a statement.
tabling member constituency	Southend West
tabling member printed	Mr David Amess
uin	216805
answer	answer is ministerial correction date of answer 09/12/2014 answer text <p>I am due to meet with the Minister for Europe on 17 December to discuss the issue of Thalidomide and will consider after that whether further representations need to be made to the German Government.</p><p> </p><p> </p><p> </p><p>I met with the Thalidomide Trust on 23 June 2014 and agreed to write to my counterpart in Germany. I subsequently wrote to Manuela Schwesig, Federal Minister of Family Affairs, Senior Citizens, Women and Youth, on behalf of all four UK Governments, asking if she would meet with the Trust.</p><p> </p> answering member constituency North Norfolk answering member printed Norman Lamb question first answered 09/12/2014 15:29:30 answering member 1439 label Biography information for Norman Lamb
tabling member	44 label Biography information for Sir David Amess

164459

registered interest
date	24/11/2014
answering body	Foreign and Commonwealth Office
answering dept id	16
answering dept short name	Foreign and Commonwealth Office
answering dept sort name	Foreign and Commonwealth Office
hansard heading	Bahrain
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Foreign and Commonwealth Affairs, what steps he plans to take following the recent death of Hasan Al-Shaikh in Bahrain as a result of alleged police torture; and how the use of torture in Bahrain will change his policy towards that country.
tabling member constituency	Southend West
tabling member printed	Mr David Amess
uin	215742
answer	answer is ministerial correction date of answer 01/12/2014 answer text <p>The British Ambassador to Bahrain has publicly raised the UK’s concern about the death of Hasan al-Shaikh at Bahrain’s Reformation and Rehabilitation Centre. A Special Investigation Unit report led to six members of staff, including three high ranking officers, appearing before the High Criminal Court on 25 November to answer charges of assaulting and torturing four men, including Al Shaikh. All six defendents pleaded not guilty and the case was adjourned until 22 December. The UK Government stands firmly against torture and cruel, inhuman, and degrading treatment or punishment, and we continue to work closely with the Government of Bahrain to share best practice on torture prevention measures.</p> answering member constituency Bournemouth East answering member printed Mr Tobias Ellwood question first answered 01/12/2014 15:09:09 answering member 1487 label Biography information for Mr Tobias Ellwood
tabling member	44 label Biography information for Sir David Amess

164460

registered interest
date	24/11/2014
answering body	Foreign and Commonwealth Office
answering dept id	16
answering dept short name	Foreign and Commonwealth Office
answering dept sort name	Foreign and Commonwealth Office
hansard heading	Bahrain
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Foreign and Commonwealth Affairs, what recent reports he has received on the arrest of Zainab Al-Khawaja in Bahrain; and if he will make a statement.
tabling member constituency	Southend West
tabling member printed	Mr David Amess
uin	215740
answer	answer is ministerial correction date of answer 01/12/2014 answer text <p>I understand that Zainab Al-Khawaja was released on bail on 19 November. Her next court hearing will be on 9 December for charges under Bahrain’s &quot;lese majeste&quot; law. The British Ambassador to Bahrain has raised the case at a senior level with the Government of Bahrain and emphasised the importance of ensuring that due legal process is respected and international norms of justice adhered to. I will continue to monitor the case closely.</p> answering member constituency Bournemouth East answering member printed Mr Tobias Ellwood question first answered 01/12/2014 15:09:58 answering member 1487 label Biography information for Mr Tobias Ellwood
tabling member	44 label Biography information for Sir David Amess

164461

registered interest
date	24/11/2014
answering body	Foreign and Commonwealth Office
answering dept id	16
answering dept short name	Foreign and Commonwealth Office
answering dept sort name	Foreign and Commonwealth Office
hansard heading	Bahrain
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Foreign and Commonwealth Affairs, what recent reports he has received on the arrest and torture of 13 women in Bahrain for organising a public referendum; and what assessment he has made on the prevalence of the use of torture in Bahrain.
tabling member constituency	Southend West
tabling member printed	Mr David Amess
uin	215741
answer	answer is ministerial correction date of answer 01/12/2014 answer text <p>I am aware of the arrest of 15 women on 16 November on suspicion of disrupting the electoral process, belonging to an illegal group and calling for the overthrow of the government. I understand that all of them have now been released, but investigations into 12 individuals continue. The British Embassy in Bahrain will continue to monitor these cases.</p><p>The UK Government stands firmly against torture and cruel, inhuman, and degrading treatment or punishment. We remain concerned by continuing allegations of torture and mistreatment in Bahrain, and continue to urge the Government of Bahrain to investigate any such allegations promptly, thoroughly and impartially.</p><p> </p> answering member constituency Bournemouth East answering member printed Mr Tobias Ellwood question first answered 01/12/2014 15:11:47 answering member 1487 label Biography information for Mr Tobias Ellwood
tabling member	44 label Biography information for Sir David Amess